WA-SEAGEN
10.11.2022 13:01:34 CET | Business Wire | Press release
Seagen Inc. (Nasdaq: SGEN) today announced that its Board of Directors has appointed David R. Epstein as Chief Executive Officer (CEO) and a member of the Board of Directors. Mr. Epstein brings more than 30 years of experience in the biopharmaceutical industry, including more than 25 years at Novartis where he built its oncology business unit from initiation to second largest in the world and then served as CEO of Novartis Pharmaceuticals, a division of Novartis AG. More recently, he was executive partner at Flagship Pioneering. In addition, Seagen announced that Roger Dansey, M.D., who has served as Seagen’s Chief Medical Officer (CMO) since 2018 and as Interim CEO since May 2022, has been appointed President, Research and Development. In this new role, Dr. Dansey will continue to serve as CMO reporting to David.
“Following a comprehensive search process, the Board selected David to serve as Seagen’s next CEO. He shares Seagen’s belief that our future is bright as we continue to build world-class capabilities in order to develop and commercialize new innovative treatments that improve the lives of patients with cancer. David’s demonstrated ability to build and scale a global oncology business, his experience in both large multi-faceted organizations and small biotechnology startups, combined with deep oncology knowledge, provide the strategic and operational expertise needed to lead Seagen to the next level,” said Felix J. Baker, Ph.D., Chair of the Board. “We are extremely grateful for Roger’s successful leadership and dedication as interim CEO. We look forward to Roger being able to focus his efforts on further strengthening our early research efforts, as he has successfully done for development, and driving the innovative engine that has been the heart of Seagen to have an even greater impact on cancer patients in the future.”
Mr. Epstein said, “I have long admired Seagen as a leader in the development and commercialization of transformative cancer therapies. Seagen is a pioneer in antibody-drug conjugate (ADC) technology with a portfolio of four approved medicines, a diverse pipeline of promising programs, and a science-driven, patient-first culture. I am honored to become CEO and work with the experienced team to further deliver on Seagen’s mission to make a meaningful difference so that people who have been diagnosed with cancer can live better lives.”
“I welcome David to the Seagen team and look forward to working closely with him as we continue to bring forward novel ADCs and other targeted treatments for cancer patients,” said Dr. Dansey. “I am excited to bring my passion for science and innovation to my expanded role overseeing research and development as we continue to deliver on the full potential of our pipeline and programs.”
About David R. Epstein
David R. Epstein has more than 30 years of drug development, deal making, commercialization and people leadership experience on a global scale. Most recently, he was executive partner at Flagship Pioneering, a builder of breakthrough bioplatform companies. From 2010 to mid-2016 he served as CEO of Novartis Pharmaceuticals, a division of Novartis AG. Previously, David started and led Novartis’ Oncology and Molecular Diagnostic units. Over the course of his career, he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Cosentyx and Entresto. Mr. Epstein holds a B.S. Degree in Pharmacy from Rutgers University College of Pharmacy and an MBA in Finance and Marketing from the Columbia University Graduate School of Business.
About Roger Dansey, M.D.
Dr. Dansey joined Seagen as CMO in 2018, bringing extensive experience in cancer drug development. Previously, he was Therapeutic Area Head for Late-Stage Oncology at Merck & Co., Inc., where he was responsible for registration efforts for Keytruda (pembrolizumab) across multiple tumor types. Earlier in his career, Dr. Dansey was the Vice President of Oncology Clinical Research at Gilead Sciences and the Global Development Lead for Xgeva (denosumab) at Amgen, where he held multiple roles in oncology and hematology.
About Seagen
Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit and follow @SeagenGlobal on Twitter.
Forward-Looking Statements
Certain of the statements made in this press release are forward looking, such as those, among others, relating to the potential of Seagen’s pipeline and programs, and the company’s efforts to build world-class capabilities in order to develop and commercialize new innovative treatments and to bring forward novel ADCs and other targeted treatments for cancer patients. Factors that may cause such a difference include, without limitation, the difficulty and uncertainty of pharmaceutical product development, the risk of adverse events or safety signals, the inability to show sufficient activity in clinical trials and the possibility of adverse regulatory actions. More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005224/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lattice Advances FPGA Design with New Leadership AI-Driven Development Tool, Lattice Prompt17.9.2026 04:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today introduced a new leadership AI-powered FPGA development tool for small and mid-range FPGAs that redefines how FPGA developers work across the full design flow. Lattice Prompt pairs with AI agentic tools developers already use, combining them with Lattice design tools, knowledge base, and documentation to turn natural language inputs into validated responses, dramatically accelerating FPGA development while optimizing design performance and capability. "Accelerating time-to-market demands and rising design complexity are putting mounting pressure on FPGA developers to do more with every design cycle," said Esam Elashmawi, Chief Strategy and Marketing Officer, Lattice Semiconductor. "Lattice Prompt gives developers AI-assisted access to the full design flow, grounded in Lattice's validated knowledge, so they can focus on what matters most: building differentiated systems." Lattice Prompt:
Lattice Expands Secure Control FPGA Leadership with New Lattice Mach-N2 Family17.9.2026 04:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced Lattice Mach™-N2 FPGA family, extending its long-running secure control FPGA leadership with new devices purpose-built for system control and security in modern infrastructure. Built on the Lattice Nexus™ 2 small FPGA platform, Mach-N2 combines integrated flash, a hardware Root of Trust, and CNSA 2.0-compliant post-quantum cryptography (PQC) with crypto agility for trusted, always-on system control and security across next-generation systems. "The demands on system control and security are accelerating as post-quantum mandates take hold, and customers building long-lifecycle infrastructure seek solutions that will help them design with today and tomorrow’s security needs in mind," said Esam Elashmawi, Chief Strategy and Marketing Officer, Lattice Semiconductor. "Mach-N2 represents a significant step forward in logic density and bandwidth while adding the most complete post-qua
TOURISE Unveils 2027 Summit Under the Theme “Alliances That Move the World”16.9.2026 22:53:00 CEST | Press release
Second global tourism summit to convene renowned leaders in Riyadh, March 23-25, 2027 First confirmed speakers announced, including leaders from Booking Holdings, Marriott, Hilton, Intrepid Travel and S4 Capital Theme calls for new alliances across tourism, technology, investment and government to shape the sector’s next 50 years Under the patronage of His Royal Highness Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, His Excellency Ahmed Al-Khateeb, Minister of Tourism and Chairman of TOURISE, today announced the TOURISE 2027 Summit, taking place in Riyadh from March 23-25, 2027. Building on the inaugural TOURISE Summit in November 2025 and a year of collaboration since, the 2027 edition will run under the theme “Alliances That Move the World.” Over three days, leaders will focus on the partnerships, investments and actions needed to advance the global tourism agenda over the next 50 years. This press release features multimedia. View the full release here
Brightfin Names Dan McNamara Chief Customer Officer16.9.2026 19:13:00 CEST | Press release
As Brightfin expands its platform and rides growing enterprise demand for IT spend control, the company taps Dan McNamara with a track record of scaling teams through rapid growth Brightfin, the leading platform for total spend intelligence in enterprise IT, today announced that Dan McNamara has joined the company as Chief Customer Officer (CCO). The appointment comes as Brightfin extends its platform into a broader vision of financial truth and operational clarity across the entire enterprise technology stack, and as more IT and finance leaders turn to Brightfin to make sense of fast-growing, fragmented spend across cloud, mobile, and emerging AI tooling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916064892/en/ Dan McNamara, CCO of Brightfin McNamara has built his career on meeting increasingly complex customer expectations. Twice, he has joined a customer organization in the middle of rapid growth and left it with a
Jazwares Partners With Sanrio to Expand Its Hello Kitty and Friends Range to EMEA16.9.2026 18:00:00 CEST | Press release
Plush Toys, Figures, and More Inspired by the Beloved World of Hello Kitty and Friends to Launch in Europe, the Middle East, and Africa Jazwares, one of the world’s leading toy companies, today announced a licensing agreement with Sanrio GmbH, extending Jazwares successful Hello Kitty and Friends toy line to Europe, the Middle East, and Africa (EMEA). The agreement will bring Sanrio’s beloved Hello Kitty and Friends characters to even more fans in the region through playful, imaginative products designed for kids and collectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916913201/en/ Jazwares partners with Sanrio to expand its Hello Kitty and Friends range to EMEA Available across key EMEA markets, the collection of trendy plush and figures, playsets, vehicles, and seasonal items reimagines Hello Kitty alongside fan-favorite friends including Cinnamoroll, Kerokerokeroppi, Pompompurin, Tuxedosam, My Melody, Kuromi, Po
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom